High protein binding and cidal activity against penicillin-resistant S. pneumoniae: A cefditoren in vitro pharmacodynamic simulation

PLoS ONE

Volumn 3, Issue 7, 2008, Pages

  Sevillano, David ^a   Aguilar, Lorenzo ^a   Alou, Luis ^a   Giménez, María José ^a   González, Natalia ^a   Torrico, Martha ^a   Cafini, Fabio ^a   Fenoll, Asunción ^b   Coronel, Pilar ^c   Prieto, José ^a  

^a SCHOOL OF MEDICINE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Tedec Meiji Farma SA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIBIOTIC AGENT; CEFDITOREN PIVOXIL; CEPHALOSPORIN DERIVATIVE; PENICILLIN G; ALBUMINOID; CEFDITOREN; PENICILLIN DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; GROWTH INHIBITION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PROTEIN BINDING; SERUM; SIMULATION; STREPTOCOCCUS PNEUMONIAE; CHEMISTRY; COMPUTER SIMULATION; HUMAN; KINETICS; METABOLISM; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; PENICILLIN RESISTANCE; ULTRAVIOLET SPECTROPHOTOMETRY;

STREPTOCOCCUS PNEUMONIAE;

ALBUMINS; CEPHALOSPORINS; CHEMISTRY, PHARMACEUTICAL; COMPUTER SIMULATION; HUMANS; KINETICS; MICROBIAL SENSITIVITY TESTS; PENICILLIN RESISTANCE; PENICILLINS; PROTEIN BINDING; SERUM; SPECTROPHOTOMETRY, ULTRAVIOLET; STREPTOCOCCUS PNEUMONIAE;

EID: 50549084089     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002717     Document Type: Article

References (30)

1. Casal J, Aguilar L, Jado I, Yuste J, Gimenez MJ, et al. (2002) Effects of specific antibodies against Streptococcus pneumoniae on pharmacodynamic parameters of beta-lactams in a mouse sepsis model. Antimicob Agents Chemother 46: 1340-1344.
2. Casa J, Gimenez MJ, Aguilar L, Yuste J, Jado I, et al. (2002) Beta-lactam activity against resistant pneumococcal strains is enhanced by the immune system. J Antimicrob Chemother 50 Suppl S2: 83-86.
3. Moeillering RC, Eliopoulos GM (2005) Principles of anti-infective therapy. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett principles and practice of infectious diseases, 6th edn. Philadelphia: Elsevier Churchill Livingstone. pp 242-253.
4. Cha R, Rybak MJ (2004) Influence of protein binding under controlled conditions on the bactericidal activity of daptomycin in an in vitro pharmacodynamic model. J Antimicrob Chemother 54: 259-262.
5. Palmer SM, Kang SL, Cappelletty DM, Rybak MJ (1995) Bactericidal killing activities of cefepime, ceftazidime, cefotaxime, and ceftriaxone against Staphylococcus aureus and beta-lactamase-producing strains of Enterobacter aerogenes and Klebsiella pneumoniae in an in vitro infection model. Antimicrob Agents Chemother 39: 1764-1771.
6. Boswell FJ, Ashby JP, Andrews JM, Wise R (2002) Effect of protein binding on the in vitro activity and pharmacodynamics of faropenem. J Antimicrob Chemother 50: 525-532.
7. Firsov AA, Smirnova MV, Lubenko IY, Vostrov SN, Portnoy YA, et al. (2006) Testing the mutant selection window hypothesis with Staphytococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother 58: 1185-1192.
8. Sevillano D, Gimenez MJ, Alou L, Aguilar L, Cafini F, et al. (2007) Effects of human albumin and serum on the in vitro bactericidal activity of cefditoren against penicillin-resistant Steptococcus pneumoniae J Antimicrob Chemother 60: 156-158.
9. Granizo JJ, Sádaba B, Honorato J, Gimenez MJ, Sevillano D, et al. (2008) Monte Carlo simulation describing the pharmacodnamic profile of cefditoren in plasma from healthy volunteers. Int J Antimicrob Agents 31: 396-398.
10. Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26: 1-10.
11. Fenoll A, Aguilar L, Robledo O, Gimenez MJ, Tarrago D, et al. (2007) Influence of the β-lactam resistance phenotype on the cefuroxime versus cefditoren suceptibility of Streptococcus pneumoniae and Haemophilus influenzae recovered from children with acute otitis media. J Antimicrob Chemother 60: 323-327.
12. Pérez-Trallero E, Marimón JM, Ercibengoa M, Giménez MJ, Coronel P, et al. (2007) Antimicrobial susceptibility of amoxicillin non-susceptible versus susceptible isolates among penicillin non-susceptible Streptococcus pneumoniae. Clin Microbiol Infect 13: 937-940.
13. Wellington K, Curran MP (2004) Cefditoren pivoxil: a review of its use in the treatment of bacterial infections. Drugs 64; 2597-2618.
14. Alvarez-Sala JL, Kardos P, Martinez-Beltran J, Coronel P, Aguilar L (2006) Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil. Antimicrob Agents Chemother 50: 1762-1767.
15. Granizo JJ, Gimenez MJ, Barberan J, Colonel P, Gimeno M, et al. (2006) The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a locus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials. Clin Ther 28: 2061-2069.
16. Fenoll A, Gimenez MJ, Robledo O, Colonel P, Gimeno M, et al. (2007) Activity of cefditoren against clinical isolates of Streptococcus pneumoniae showing non-susceptibility to penicillins, cephalosporins, macrolides, ketolides or quinolones. Int J Antimicrob Agents 29: 224-226.
17. Clinical Laboratory Standards Institute. Methods for dillution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th ed. CLSI document M7-A7. CLSI, Wayne, PA, USA, 2006.
18. Grasso S, Meinardi G, de Carneri I, Tamassia V (1978) New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity. Antimicrob Agents Chemother 13: 570-576.
19. Mulford D, Mayer M, Witt G (2000) Effect of age and gender on the pharmacokinetics of cefditoren. In: Abstracts of the fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto 2000, Abstract 310. Washington, DC, USA: American Society for Microbiology.
20. Mulford D, Mayer M, Witt G (2000) Effect of renal impairment on the pharmacokinetic of cefditoren. In: Abstracts of the fortienth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto 2000, Abstract 311. Washington, DC, USA: American Society for Microbiology.
21. Sadaba B, Azanaza JR, Quetglas EG, Campanero MA, Honorato J, et al. (2007) Pharmacokinetic/pharmacodynamic serum and urine profile of cefditoren following single-dose and multiple twice- and thrice-daily regimens in healthy volunteers: A phase I study. Rev Esp Quimioter 20: 51-60.
22. Craig WA, Suh B (1991) Protein binding and the antimicrobial effects: methods for the determination of protein binding. In: Lorian V, ed. (1991) Antibiotics in laboratory medicine, 3rd ed. Philadelphia: Williams and Wilkins. pp 367-402.
23. Doumas BT, Watson WA, Biggs HG (1971) Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta 31: 87-96.
24. Andrews JM (1999) Microbiological assays. In: Reeves DS, Wise R, Andrews JM, White LO, eds. Clinical Antimicrobial Assays, 1st edn. Oxford: Oxford University Press. pp 35-44.
25. Alou L, Gimenez MJ, Sevillano D, Aguilar L, Gonzalez N, et al. (2007) Are beta-lactam breakpoints adequate to define non-susceptibillity for all Haemophilus influenzae resistance phenotypes from a pharmacodynamic point of view?. J Antimicrob Chemother 59: 652-657.
26. MacGowan AP, Noel AR, Rogers CA, Bowker KE (2004) Antibacterial effects of amoxicillin-clavulanate against Streptococus pneumoniae and Haemophilus influenzae strains for which MICs are high, in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 48: 2599-2603.
27. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement, M100-S18. CLSI, Wayne, PA, USA, 2008.
28. Cefditoren package insert. www.fda.gov.
29. Sevillano D, Calvo A, Gimenez MJ, Allou L, Aguilar L, et al. (2004) Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation. J Antimicrob Chemother 54: 1148-1151.
30. Azoulay-Dupuis E, Moine P, Bedos JP, Rieux V, Vallee E (1996) Amoxicillin dose-effect relationship with Steptococcus pneumoniae in a mouse pneumonia model and roles of in vitro penicillin susceptibilities, autolysis, and tolerance properties of the strains. Antimicrob Agents Chemother 40: 941-946.